PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Floretyrosine F 18→

Floretyrosine F 18 PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
178433-03-9
Molecular formula
C11H14[18F]NO3
Molecular weight
226.238 g/mol
Drug class
18F-labelled amino-acid PET radiotracerdiagnostic imaging agent
Mechanism of action
Radiolabelled fluoroethyltyrosine is transported into cells by large neutral amino acid transporters (LAT1/LAT2). Increased uptake in metabolically active tumour tissue can support PET imaging; it is a diagnostic radiopharmaceutical, not a therapeutic tyrosine analogue.
Indications / reported uses
  • PET imaging of brain tumours in adults with cognitive impairment or suspected glioma to assist assessment of amino-acid transport and tumour activity under the specific radiopharmaceutical product authorisation; the exact intended use is jurisdiction- and product-specific

Sources: PubMed — 18F-fluoroethyltyrosine PET imaging · NLM MeSH — Fluoroethyltyrosine F18 · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Floretyrosine F 18 PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Floretyrosine F 18 Permitted Daily Exposure (PDE) report (the Floretyrosine F 18 PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Floretyrosine F 18 Occupational Exposure Limit (OEL) report (the Floretyrosine F 18 OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.